Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-22 · accession 0001628280-26-011331 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-24 | 2026-02-22 | VIR | Sabatini Brent | SVP, CAO | A - Grant | $0.00 | +25.0K | 72.9K | +52% | $0 |
| D | 2026-02-24 | 2026-02-23 | VIR | Sabatini Brent | SVP, CAO | S - Sale | $7.45 | -1,829 | 71.0K | -3% | -$13.6K |
| D | 2026-02-24 | 2026-02-22 | VIR | Sabatini Brent | SVP, CAO | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-22 | A | A | 25,000 | $0.00 | 72,872 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-23 | S | D | 1,829 | $7.45 | 71,043 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-02-22 | A | A | 50,000 | $0.00 | 50,000 | D | $7.56 · — to 2036-02-21 | 50,000 Common Stock | (F3) 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. |